Introduction Postmenopausal osteoporosis (PMO) affects millions of women worldwide and is a leading cause of fractures and disability in aging populations (1). Timely pharmacological intervention significantly reduces fracture risk, yet treatment gaps persist especially in patients at high or very high risk (2). While antiresorptive like bisphospho
155 Reached
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Complicated case of Osteoarthritis
1849 Reached2 Comments3 Likes
Vildagliptin in Reducing Risk of Post-partum Diabetes
2384 Reached7 Comments4 Likes
Managing Amenorrhea in Adolescent girl
2544 Reached5 Comments4 Likes